Advanced search
Start date
Betweenand

Investigation of Stathmin 1 and microtubule instability in phenotype of hematological neoplasms

Grant number: 17/24993-0
Support type:Regular Research Grants
Duration: May 01, 2018 - April 30, 2020
Field of knowledge:Health Sciences - Medicine
Principal Investigator:João Agostinho Machado Neto
Grantee:João Agostinho Machado Neto
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Acute leukemias comprise a group of hematological malignancies characterized by the expansion of blasts in bone marrow and peripheral blood, which is mainly due to the loss of differentiation ability of stem cells to functional cells in terminal stage, deregulation of proliferation and resistance to apoptosis. The mortality of adult patients with acute leukemia is very high, making it imperative to identify new molecular markers and signaling pathways that may be useful in prognostic definition, therapeutic response and the development of new treatment options. Stathmin 1 is a microtubule destabilizing protein that includes multiple signaling pathways and has been described as potentially regulated by oncogenes associated with hematological malignancies, including JAK2V617F, PML-RAR± and BCR-ABL1. In addition, Stathmin 1 is highly expressed in leukemia cells and Stathmin 1 inhibition reduces the proliferation and clonogenicity. However, the clinical impact of Stathmin 1 expression, as well as, the consolidation of this protein as a potential therapeutic target in hematological malignancies remains poor explored. The aims of the present project are (i) to investigate the impact of Stathmin 1 expression in the clinical outcome of a well-characterized cohort of patients with acute promyelocytic leukemia, (ii) to investigate the effects of Stathmin 1 inhibition in leucemia cells in vitro and in vivo models, (iii) to identify and/or validate compounds capable of inhibiting Stathmin 1 and/or cause microtubules stability and to characterize them at cellular and molecular level. (AU)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
LIMA, KELI; ELIAS GODOY CARLOS, JORGE ANTONIO; ALVES-PAIVA, RAQUEL DE MELO; VICARI, HUGO PASSOS; DE SOUZA SANTOS, FABIO PIRES; HAMERSCHLAK, NELSON; COSTA-LOTUFO, LETICIA VERAS; TRAINA, FABIOLA; MACHADO-NETO, JOAO AGOSTINHO. Reversine exhibits antineoplastic activity in JAK2(V)(617)(F)-positive myeloproliferative neoplasms. SCIENTIFIC REPORTS, v. 9, JUL 9 2019. Web of Science Citations: 0.
LIMA, KELI; COELHO-SILVA, JUAN LUIZ; KINKER, GABRIELA SARTI; PEREIRA-MARTINS, DIEGO ANTONIO; TRAINA, FABIOLA; CARLOS MAGNO FERNANDES, PEDRO AUGUSTO; MARKUS, REGINA PEKELMANN; LUCENA-ARAUJO, ANTONIO ROBERTO; MACHADO-NETO, JOAO AGOSTINHO. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. CANCER GENETICS, v. 233, p. 56-66, APR 2019. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.